Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 10-11
Submit an article Journal homepage
1,729
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014–2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy

Hege KilengDepartment of Clinical Medicine, Gastroenterology and Nutrition Research Group, UiT The Arctic University of Norway, Tromsø, Norway; ;Department of Medicine, University Hospital of North Norway, Tromsø, Norway; View further author information
,
Midori KjellinDepartment of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden; View further author information
,
Dario AkaberiDepartment of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden; View further author information
,
Assar BergforsDepartment of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden; View further author information
,
Ann-Sofi DubergDepartment of Infectious Diseases, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Lars WesslénGävle Hospital, Gävle, Sweden; View further author information
,
Astrid DanielssonFalun Hospital, Falun, Sweden; View further author information
,
Magnhild Gangsøy KristiansenNordlandssykehuset Bodø, Department of Clinical Medicine (IKM), UiT The Artic University of Tromsø, Norway; View further author information
,
Tore GuttebergDepartment of Medical Biology, Research Group for Host-Microbe Interactions, UiT The Arctic University of Norway, Tromsø, Norway; ;Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; View further author information
,
Rasmus GollDepartment of Clinical Medicine, Gastroenterology and Nutrition Research Group, UiT The Arctic University of Norway, Tromsø, Norway; ;Department of Medicine, University Hospital of North Norway, Tromsø, Norway; View further author information
,
Anders LannergårdDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University Hospital, Uppsala, SwedenView further author information
&
Johan LennerstrandDepartment of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden; Correspondence[email protected]
View further author information
 show all
Pages 1347-1353 | Received 07 Mar 2018, Accepted 27 Apr 2018, Published online: 05 Nov 2018

References

  • Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int. 2009;29:89–99.
  • Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
  • Büsch K, Waldenström J, Lagging M, et al. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scand J Gastroenterol. 2017;52:61–68.
  • Dalgard O, Jeansson S, Skaug K, et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38:864–870.
  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31:30–60.
  • Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327.
  • Palanisamy N, Danielsson A, Kokkula C, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12–17.
  • Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
  • Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64–71.
  • Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance–associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.
  • Wyles DL. Resistance to DAAs: when to look and when it matters. Curr Hiv Aids Rep. 2017;14:229–237.
  • Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–380.
  • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
  • Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015;62:1008–1014.
  • Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
  • Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544–1553.
  • AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. [www.hcvguidelines.org]. 2017. Available from: https://www.hcvguidelines.org/
  • EASL guidelines 22 Sept. 2016. www.easl.eu/medias/cpg/HCV2016/Summary.pdf
  • Stockholm: Janusinfo. 2017 [cited 2017 Jul 4]. Available from: http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Hepatit-C-161215.pdf
  • Faglig Veileder for Utredning og Behandling av Hepatitt C: Den Norske Legeforening. 2014 [cited 2018 Jan 8]. Available from: http://legeforeningen.no/PageFiles/246436/Veileder%20sept%202014.pdf
  • Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289.
  • Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.
  • Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–512.
  • Lindström I, Kjellin M, Palanisamy N, et al. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Infect Dis. 2015;47:555–562.
  • Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360–369.
  • Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.